Novo Nordisk announced a $506 million investment to expand its manufacturing facility in Monksland, Athlone, Ireland, significantly increasing production capacity for current and future GLP-1 treatments.

The investment marks a major strategic milestone for the company and reinforces its long-term commitment to Ireland and global healthcare innovation.¹

What is included in the expansion?

The upgraded tableting facility will expand manufacturing capabilities for oral products, strengthen supply outside the United States, and position Ireland as a key hub serving international markets.¹

The project includes upgrades and retrofitting of the existing site to enhance production of oral GLP-1 medicines.

Kasper Bødker Mejlvang, executive vice president of CMC & product supply at Novo Nordisk, said the expansion will strengthen the company’s ability to meet growing demand for oral treatments beyond the U.S. He described the investment as a historic milestone for Novo Nordisk in Ireland and reaffirmed the company’s commitment to its workforce in Athlone and to improving the lives of people living with serious chronic diseases.

“With the investment in the Athlone facility, Novo Nordisk is expanding its production capacities for oral products, which will strengthen our ability to meet both current and future demand, outside the U.S.,” added Mejlvang. “This investment, a historic milestone for Novo Nordisk in Ireland, marks our continued commitment to Ireland and our highly skilled employees in Athlone while allowing us to make a difference for millions of people living with serious chronic diseases.”

Will the site expansion create jobs?

The facility currently employs 260 people, who are expected to continue focusing on delivering high-quality oral treatments efficiently and sustainably.¹ The broader development project, covering 45 acres is expected to create up to 500 construction jobs.¹ Construction is already underway and will be completed in phases from late 2027 through 2028.

Why is Novo Nordisk investing in GLP-1 manufacturing?

Novo’s decision to invest in GLP-1 manufacturing comes on the heels of its recently approved and launched Wegovy oral pill.

The oral GLP-1 offers a new option for more than 100 million Americans living with obesity, delivering the same GLP-1–based science as injectable Wegovy in an oral form.²

Novo Nordisk emphasized its efforts to expand access through retail pharmacies, telehealth providers and direct-to-patient options, while helping patients obtain FDA-approved medicines and avoid unapproved alternatives.²

“Wegovy pill is here, and it represents a significant innovation as the first and only GLP-1 pill for weight loss. This moment is about changing what's possible in weight management, and to make that possible, we have worked to ensure Wegovy pill is affordable and accessible to those who need it, however they choose to receive their care,” said Ed Cinca, senior vice president, marketing & patient solutions at Novo Nordisk.

With the continued growth in demand, the company has placed increased emphasis on manufacturing GLP-1 products and maintaining steady inventory to match patient need and demands, highlighting the company’s decision to invest in its manufacturing capabilities.

Sources

1. Novo Nordisk announces more than 400 million euro expansion in its manufacturing facility in Athlone, Ireland Novo Nordisk March 2, 2026 https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916508
2. Novo Nordisk's Wegovy pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America Novo Nordisk January 5, 2026 https://www.prnewswire.com/news-releases/novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-now-broadly-available-across-america-302652205.html